• Mutation; HGNC; HGNC:886; ATRX; Unexplicit; Ex2-10del; Zygosity=Hemizygous (PubMed=31631027).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Glu286Lys (c.856G>A); ClinVar=VCV000183752; Zygosity=Homozygous (PubMed=11507071; DepMap=ACH-001481).
  

PubMed=9850071
Keshelava N., Seeger R.C., Groshen S., Reynolds C.P.
Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy.
Cancer Res. 58:5396-5405(1998)

PubMed=11212268
Thompson P.M., Maris J.M., Hogarty M.D., Seeger R.C., Reynolds C.P., Brodeur G.M., White P.S.
Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma.
Cancer Res. 61:679-686(2001)

PubMed=11507071
Keshelava N., Zuo J.J., Chen P., Waidyaratne S.N., Luna M.C., Gomer C.J., Triche T.J., Reynolds C.P.
Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines.
Cancer Res. 61:6185-6193(2001)

PubMed=15150091; DOI=10.1158/0008-5472.CAN-03-0809
Schaefer K.-L., Brachwitz K., Wai D.H., Braun Y., Diallo R., Korsching E., Eisenacher M., Voss R., van Valen F., Baer C., Selle B., Spahn L., Liao S.-K., Lee K.A.W., Hogendoorn P.C.W., Reifenberger G., Gabbert H.E., Poremba C.
Expression profiling of t(12;22) positive clear cell sarcoma of soft tissue cell lines reveals characteristic up-regulation of potential new marker genes including ERBB3.
Cancer Res. 64:3395-3405(2004)

PubMed=20922763; DOI=10.1002/pbc.22801; PMCID=PMC3005554
Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J., Reynolds C.P.
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.
Pediatr. Blood Cancer 56:239-249(2011)

PubMed=24792489; DOI=10.1007/s11060-014-1456-8
Farooqi A.S., Dagg R.A., Choi L.M.R., Shay J.W., Reynolds C.P., Lau L.M.S.
Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations.
J. Neurooncol. 119:17-26(2014)

PubMed=31631027; DOI=10.1016/j.ccell.2019.09.002; PMCID=PMC6851493
Qadeer Z.A., Valle-Garcia D., Hasson D., Sun Z., Cook A., Nguyen C., Soriano A., Ma A.-Q., Griffiths L.M., Zeineldin M., Filipescu D., Jubierre L., Chowdhury A., Deevy O., Chen X., Finkelstein D.B., Bahrami A., Stewart E., Federico S.M., Gallego S., Dekio F., Fowkes M.E., Meni D., Maris J.M., Weiss W.A., Roberts S.S., Cheung N.-K.V., Jin J., Segura M.F., Dyer M.A., Bernstein E.
ATRX in-frame fusion neuroblastoma is sensitive to EZH2 inhibition via modulation of neuronal gene signatures.
Cancer Cell 36:512-527.e9(2019)